Search - tctmd.com

Displaying 61 - 80 of 315

Sort: Relevancy | Date

News Conference News EuroPCR 2018

New Bioresorbable Scaffold, Magmaris, Delivers Positive Early Outcomes

Michael O'Riordan

May 25, 2018

News Conference News EuroPCR 2018

Balking at Bulk: SORT-OUT VIII Hints at Clinical Edge for Thinner-Strut Stents

Shelley Wood

May 24, 2018

News Industry News

Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR

May 24, 2018

News Industry News

Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease

May 23, 2018

News Conference News SCAI 2018

Interventional Appetite Erodes for Dissolving Polymers and Scaffolds

Shelley Wood

May 04, 2018

News Conference News ACC 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Michael O'Riordan

March 11, 2018

News Daily News

Meta-analysis Supports Benefits of Short-term DAPT Among Elderly Patients

Yael L. Maxwell

February 20, 2018

News Daily News

One in Five CABG Patients Develop New-Onset Atrial Fibrillation: EXCEL

Michael O'Riordan

February 12, 2018

News Industry News

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

December 06, 2017

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

News Conference News TCT 2017

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Todd Neale

October 30, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day One

Shelley Wood

October 30, 2017

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

News Daily News

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Michael O'Riordan

October 11, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2017

Shelley Wood

September 30, 2017

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Daily News

No More Absorb BVS: Abbott Puts a Stop to Sales

Caitlin E. Cox

September 08, 2017

News Conference News ESC 2017

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

Shelley Wood

August 30, 2017

News Daily News

Boston Scientific Scraps Biodegradable Scaffold Program

Michael O'Riordan

August 01, 2017

News Industry News

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

July 25, 2017

Advertisement

New Bioresorbable Scaffold, Magmaris, Delivers Positive Early Outcomes

Balking at Bulk: SORT-OUT VIII Hints at Clinical Edge for Thinner-Strut Stents

Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR

Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease

Interventional Appetite Erodes for Dissolving Polymers and Scaffolds

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Meta-analysis Supports Benefits of Short-term DAPT Among Elderly Patients

One in Five CABG Patients Develop New-Onset Atrial Fibrillation: EXCEL

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

Long-term Absorb BVS Data Continue to Disappoint

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Live From Denver: TCT 2017, Day One

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

TCTMD’s Top 10 Most Popular Stories for September 2017

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

No More Absorb BVS: Abbott Puts a Stop to Sales

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

Boston Scientific Scraps Biodegradable Scaffold Program

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content